EssexBio

COMPANY NEWS

EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®

2025.12.17 Download

Hong Kong, 17 December 2025

Essex Bio-Technology Ltd. ("EssexBio" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma") has established a strategic collaboration with Kenvue China (“Kenvue”), a leader in consumer health. Under the collaboration, Essex Medipharma will leverage its extensive commercial network to promote, educate and market selected Kenvue products. The cooperation focuses on professional channel engagement, medical education activities, and brand promotion within healthcare settings.

The collaboration encompasses a selected portfolio of trusted Kenvue brands—including Rhinocort® (Budesonide Nasal Spray), Motrin® (Ibuprofen Suspension/Drops), and Tylenol® (Paracetamol Drops/Suspension) —which are widely recognized by healthcare professionals and patients for their reliability in the management of allergies, fever, and cold symptoms.

“Our cooperation with EssexBio marks the beginning of a new chapter for Kenvue in strengthening local partnerships and deepening our commitment to the Chinese market”, said Gift Arpaporn Samabhandhu, President of Kenvue China. “We sincerely look forward to working closely with our new partners to jointly promote the high-quality development in the healthcare industry and improve the health and well-being of patients and consumers in China.”

The collaboration is in line with Essexbio’s business strategy aiming at boosting its presence in the Chinese healthcare market, leveraging its extensive commercial network and experience. By combining their expertise, Essexbio and Kenvue can effectively accelerate the awareness and commercial footprint of these products and better meet the clinical needs of more patients.

~ End ~

About Kenvue
Kenvue (NYSE: KVUE) is a global leader in consumer health. Formerly Johnson & Johnson Consumer Health, the company brings more than 135 years of experience and expertise to the industry. Its portfolio of iconic brands—including Aveeno®, Band-Aid®, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®—is widely trusted by healthcare professionals and consumers worldwide for its strong scientific foundation and proven efficacy.

About EssexBio (1061.HK)
EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(適麗順®) (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology.These products are marketed and sold through approximately 14,100 hospitals, supported by the Company’s 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Related news